Rufinamide approved as adjunctive for Lennox Gastaut syndrome
The U.S. Food and Drug Administration has approved a new drug, Banzel (rufinamide), for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome. “This approval offers another treatment option for patients who suffer from these debilitating, severe seizures,” said Russell Katz, M.D., director of the Division of Neurology Products in the FDA’s […]